This Beaten-Down Artificial Intelligence (AI) Stock Just Got Some Great News: Time to Buy?

Artificial intelligence (AI) is taking over the world. Individuals and corporations are implementing the technology in their day-to-day lives and operations; governmental institutions are doing the same. The U.S. Food and Drug Administration (FDA) recently announced it would phase out animal testing in drug development in favor of other methods, including AI-based testing.That's good news for Recursion Pharmaceuticals (NASDAQ: RXRX), a biotech company that's already pioneering the use of AI in drug development. Recursion's shares soared on the news, but the stock remains down significantly over the trailing-12-month period. Should investors purchase shares today?Recursion Pharmaceuticals built the largest AI supercomputer in the pharmaceutical industry with the help of tech giant Nvidia. The company's operating system (OS) features a library of human genes, and helps predict whether various clinical compounds would effectively treat certain diseases. The most promising compounds get to move on to clinical trials.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool